MOXONIDINE THERAPY, HEART AND CAROTID ARTERIES REMODELING IN HYPERTENSIVE POSTMENOPAUSAL WOMEN WITH METABOLIC SYNDROME: PP.34.442

Abstract

Study Objective: To evaluate influence of moxonidine therapy on carotid wall thickness, heart structural and functional parametres in hypertensive postmenopausal women with metabolic syndrome (MS). Material and Methods: 26 hypertensive (AH grades 1–2) postmenopausal women with metabolic syndrome 45–55 years old (52,5+/−0,4 years). MS was diagnosed according to ESC-ESH (2007) criteria. Patients were treated with moxonidine (200–600 mcg/day) orally. Structure and function of the heart and the intima-media thickness of carotid arteries were reviewed by ultrasound method before therapy and on 12-th week of treatment with moxonidine. Statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL, USA). Results: 14 (53,8%) hypertensive postmenopausal women with MS had elevated left ventricle mass index (LVMI more than 110 g/m2). 9 (34,6%) patients had LV diastolic dysfunction. We revealed correlation between LVMI, interventricular septum thickness, E/A ratio and systolic BP (r = 0,4; 0,4 and -0,4, accordingly; p = 0,02; 0,04 and 0,02 accordingly). Positive correlation was revealed between interventricular septum thickness and diastolic BP (r = 0,4; p = 0,07); left atrium diameter and diastolic BP (r = 0,4; p = 0,04). Results: Moxonidine therapy did not changed intima-media thickness of carotid arteries (0,86+/−0,03 mm vs 0,81+/−0,04 mm; p = 0,05) and LVMI (114,0+/−3,4 g/m2 and 113,9+/−3,4 g/m2, p > 0,05). LV diastolic function improved: E/A ratio increased from 1,05+/− 0,03 to 1,20+/− 0,03 (p Conclusion: Moxonidine therapy improved left ventricle diastolic function and decreased left atrium diameter and left atrium volume in hypertensive postmenopausal women with metabolic syndrome.